tbuckley/cabot-search huggingface dataset:
Abstract P073: A Novel Epigenetic Link Between Gestational Diabetes Mellitus and Macrosomia
Authors: Brian Joyce, Huikun Liu, Leishen Wang, Jun Wang, Yinan Zheng, Drew Nannini, Alex Drong, Stephanie Shiau, Weiqin Li, Junhong Leng, Yun Shen, Ru Gao, Gang Hu, Andrea Baccarelli, Lifang Hou
Journal: Circulation (2019)

Background: Gestational diabetes mellitus (GDM) is a known risk factor for macrosomia, with recent estimates suggesting that between 15-45% of newborns of mothers with GDM are macrosomic (vs. 12% in non-GDM mothers). This study’s objectives were to explore associations between both maternal GDM and children’s macrosomia and DNA methylation of eight genes selected based on a literature review of candidates potentially involved in GDM and obesogenic pathways ( IGF1 , IGF2 , H19 , ARHGRF11 , MEST , NR3C1 , Adiponectin , and RETN ). Methods: Data were taken from the Tianjin GDM Observational study, in the 4th-largest city in China; subjects were ages 24-49 and diagnosed with GDM between 2005-2009. Baseline surveys were completed from 2009-2011 for 580 enrolled women-child pairs; an additional 580 women-child pairs without GDM and frequency matched on child sex and birth date were enrolled. We examined 572 GDM cases vs. 573 non-GDM controls; of these 177 children were born with macrosomia (114 to women with GDM, p&lt;0.001). Anthropometric measurements of all enrolled women were completed as part of usual prenatal care; blood draws for DNA methylation analysis (using the Illumina 850K array) were collected from children (median age 5.9 years, range 3.1-10.0). We used logistic regression for all analyses and adjusted for maternal height, age, smoking status, pre-pregnancy overweight/obesity, weight gain during pregnancy, parity, and hypertensive disorders of pregnancy as well as child sex and gestational age at delivery. FDR adjustment was used to correct all candidate gene CpG analyses for multiple testing, with FDR-adjusted P&lt;0.05 considered statistically significant. Results: After analysis of 345 CpGs in eight target genes, one CpG was associated with macrosomia (cg14428359) and one with GDM (cg19466922) at FDR &lt; 0.05; both CpGs were located in the gene MEST (3’ and 5’ untranslated regions, respectively). One additional CpG site in the promoter region of MEST (cg05862114) was associated with both GDM and macrosomia before FDR adjustment. All three CpGs were hypomethylated in both children of GDM mothers and macrosomia cases. Conclusions: MEST is a paternally imprinted gene that is highly expressed in fetal and placental tissue, and believed to play an important role in fetal development. It has also been found to have elevated expression in adipose tissue; epigenetic regulation of MEST may play an important role in the link between GDM and macrosomia.
Body Mass Index as a Potential Confounder for Oncological Outcomes Following Autologous Fat Transfer
Authors: Edel Marie Quinn, J. Mitchel Barry, Siun Walsh
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
The association between GAD65 antibody levels and incident Type 2 Diabetes Mellitus in an adult population: A meta-analysis
Authors: Anitra D.M. Koopman, Joline W. Beulens, Ellis Voerman, Simone P. Rauh, Amber A. van der Heijden, Timothy J. McDonald, Marlous Langendoen - Gort, Femke Rutters
Journal: Metabolism (2019)
Abstract P233: Correlations Between Grocery Purchase Quality Index Scores and Healthy Eating Index Scores Vary by Demographics and Shopping Habits
Authors: Haley W Parker, Anne N Thorndike, Maya Vadiveloo
Journal: Circulation (2019)

Introduction: The Grocery Purchase Quality Index (GPQI) is a new, objective diet quality index that assesses adherence of household grocery purchases to the US Dietary Guidelines. Currently, little is known about the correlation between the GPQI and other common diet quality metrics like the Healthy Eating Index (HEI), and whether shopper characteristics (e.g., demographics, shopping habits) influence the strength of this correlation and the utility of the GPQI as a tool for tracking diet quality. Hypothesis: The GQPI and HEI-2010 will be moderately correlated at baseline in a cohort of shoppers enrolled in a study testing strategies to promote healthier grocery purchases, and these correlations will vary by shopper characteristics. Methods: Data from 224 households recruited from a single medium-sized grocery store were analyzed. Eligible participants were ≥18y, the primary shopper of their household, and did ≥50% of household shopping at store. Participants completed a baseline (Aug-Oct 2018) validated online food frequency questionnaire (FFQ) and a questionnaire about demographics and shopping habits. HEI-2010 scores were calculated from FFQs and GPQI scores were calculated from 2-6 weeks of baseline purchasing data; higher scores reflected healthier diets. Correlations between HEI and GQPI scores (reported as percent of total score) were calculated in SAS 9.4 for the overall sample and by demographic characteristics and shopping habits of interest. Results: The sample was predominantly female (90%), older (mean age=55.6±13.7), and higher socioeconomic status (47.9% &gt;college degree, 49.7% household income &gt;$100k). The mean HEI score was 73.0±9.3% out of 100pts, the mean GQPI score was 54.5±11.4% out of 75pts, and the mean BMI was 25.4±4.6. The two scores were moderately correlated in the overall sample (r=0.31, p&lt;0.001); correlations were stronger in men (r=0.52, p=0.02), middle-income ($60-100k) households (r=0.51, p=0.001), and individuals with underweight (n=14, r=0.58, p=0.03), and obesity (r=0.39, p=0.04) and weaker in individuals with normal weight (r=0.28, p=0.003). The GPQI and HEI were not correlated for individuals with overweight (r=0.16) low-income (&lt;$60k) households (r=0.16) or for those who shopped at farmer’s markets within the past month (r=0.15) whereas individuals who shopped at other grocery or superstores (r=0.31-0.35) had correlations similar to the overall sample. Conclusion: These findings suggest that food purchasing data reflects the individual diet quality and may be a promising tool for evaluating and monitoring individual-level diet quality. Further research should explore influential demographics and shopping habits on the strength of the correlation between the GQPI and HEI to develop more accurate predictive models using objective household purchasing data as a proxy for individual-level intake.
MID-DAY SLEEP EFFECTS AS POTENT AS RECOMMENDED LIFESTYLE CHANGES IN PATIENTS WITH ARTERIAL HYPERTENSION
Authors: Leonidas Poulimenos, Manolis Kallistratos, Pavlos Tsinivizov, Nikolaos Kouremenos, Nestoras Kontogiannis, Andreas Pittaras, Andreas Triantafyllis, Aggeliki Koukouzeli, Konstantinos Kyfnidis, Athanasios Manolis
Journal: Journal of the American College of Cardiology (2019)
Abstract 004: Novel Serum Metabolites Associate With Diastolic Function: Evidence From the Bogalusa Heart Study
Authors: Alexander C Razavi, Camilo Fernandez, Xuenan Mi, Jiang He, Lydia Bazzano, Jovia Nierenberg, Shengxu Li, Tanika N Kelly
Journal: Circulation (2019)

Introduction: Diastolic dysfunction is one key causal factor for heart failure with preserved ejection fraction (HFpEF). We conducted a metabolome-wide association study to identify novel diastolic function-related metabolites in relatively young and healthy adults. Hypothesis: We hypothesized that serum metabolites could predict diastolic function and thus potentially serve as biomarkers for subclinical disease. Methods: The study cohort consisted of 1,038 participants of the Bogalusa Heart Study (34.9% black, 57.3% females, aged 33.6-57.5 years). Diastolic function was assessed via 2D and tissue doppler echocardiography, and included peak early filling velocity (E), peak velocity caused by atrial contraction (A), medial mitral annular velocity (e’), left ventricular isovolumic relaxation time (IVRT), as well as deceleration time (DT). Untargeted metabolomic analysis of fasting serum samples was conducted. Multivariable-adjusted linear regression models were employed to assess the relationship of metabolites with echocardiographic measures of diastolic function. Results: Following quality control, 1202 metabolites were tested for association with E/A ratio, E/e’ ratio, IVRT, and DT. After Bonferroni correction, 9 novel metabolites, derived from amino acid, cofactor, energy, lipid, and nucleotide pathways, were significantly associated with diastolic function in blacks with nominal significance and consistent effect direction in whites (Table). Of these significant metabolites, 2 and 6 metabolites were associated with the E/A ratio and E/e’ ratio, respectively. No significant associations of metabolites with IVRT or DT were found. Fatty acid metabolism was the biological sub-pathway most represented in significant diastolic function-metabolite associations. Conclusion: The current study identified novel metabolites associated with diastolic function, suggesting that the serum metabolome, and its underlying biological pathways, may be implicated in HFpEF pathogenesis.
Prognostic value of p53 expression in early stage low grade endometrioid endometrial cancer.
Authors: Woojin Chong, Bryan Harmon, Anne R. Van Arsdale, Nicole Nevadunsky, Kathleen Whitney, Gary L. Goldberg, Merieme Klobocista
Journal: Journal of Clinical Oncology (2015)

e16510 Background: Low grade endometrioid EC is the most common subtype and is usually estrogen dependent and associated with mutations in PTEN. Overexpression of p53 correlates with poor prognosis in high grade EC. Low grade EC has a low rate of p53 expression (3-52%). The aim of this study is to assess the prognostic value of p53 expression in low grade early stage EC. Methods: Patients treated for stage I-II, grade 1 and 2 endometrioid EC from 1999-2010 were identified. Demographic and clinicpathologic data were abstracted from medical records and summarized as appropriate for continuous, categorical and non-normally distributed variables. Immunohistochemistry was performed using antibodies to estrogen receptor (ER), progesterone receptor (PR) and p53. The staining intensity and percentage of positive cells were scored and expression levels compared using H scores (product of intensity and percentage of positive cells). Associations between demographic, histopathologic characteristics and median ER/PR/p53 H scores were assessed using t-tests, Fisher’s exact test, or Wilcoxon rank-sum test as appropriate. Results: 107 out of 430 patients were complete for analysis. Clinical/pathologic data are shown in table 1. 21 patients received adjuvant therapy. 4 patients recurred. Larger tumor size was associated with myometrial invasion (p = .008) and lower ER H score. Grade 2 was associated with a higher rate of LVI (p = .04), lower ER H score (p = .02) and PR H score (p = .03). There was no difference in p53 H score between grade 1 and 2 tumors. The presence of LVI was associated with myometrial invasion (p < .001), lower ER H score (p = .001) and lower p53 H score (p = .04). Deep myometrial invasion was associated with lower ER H score (p = .05) but no difference in PR or p53 H score. Conclusions: Low expression of ER is associated with poor prognostic variables in low grade EC. Interestingly, LVI was associated with lower p53 H score. This will need confirmation with analysis of the full cohort. Mean Age at diagnosis (years) 62 BMI (kg^m2) 35.5 Ethnicity N (%) Caucasian 57 (53.3) African American 18 (16.8) Hispanic 23 (21.5) Other 3 (2.8) Surgical procedure TAH/BSO 40 (37.4) TAH/BSO/Staging 67 (62.6) Grade 1 83 (77.6) 2 24 (22.4)
Evaluation of prevalence and cost burden of comorbidities among patients with chronic myeloid leukemia (CML) in the U.S.
Authors: Jay Lin, Dinara Makenbaeva, Clara Chen, Melissa Lingohr-Smith, Bjorn Bolinder
Journal: Journal of Clinical Oncology (2015)

e17677 Background: National Comprehensive Cancer Network (NCCN) treatment guidelines note that for the treatment of CML with the 2nd generation tyrosine kinase inhibitors (TKIs), certain comorbidities should be taken into consideration. The guidelines state that nilotinib may be more appropriate for CML patients with a history of lung disease or who are at risk for pleural effusions, while dasatinib may be more appropriate for those with a history of arrhythmias, heart disease, or pancreatitis. This study aimed to determine the prevalence of comorbidities relevant to TKI treatment and their associated cost burdens in the US. Methods: Patients with CML were identified from the MarketScan Commercial and Medicare claims databases between 1/1/2007 and 09/30/2013. All patients were required to have a 12-month baseline period before the first CML diagnosis to identify comorbidies, and follow-up (FU) was standardized to 18 months. Patients received ≥1 TKI prescription during the FU period. Prevalence and cost data were derived for comorbidities mentioned in the NCCN guidelines. For each comorbidity, mean medical cost per patient (MMCPP) were evaluated from the claims with ICD-9 codes for that condition during the 18-month FU. Results: This study identified 2,067 CML patients (median age, 58 years; range: 18-93 years; 55% male). The most prevalent comorbidity was heart disease (14.4%) with a MMCPP of $2,590, followed by diabetes (11.7%) with a MMCPP of $1,610 (table). The prevalence of lung disease, arrhythmia, and pancreatitis were 7.6%, 3.5%, and 0.2% respectively (table). Conclusions: The prevalence of comorbidities relevant to TKI treatment is sizeable among CML patients, with heart disease as the most prevalent and costly. These comorbidities should be taken into consideration when selecting appropriate TKI treatment for CML patients to manage the clinical and economic burden associated with such conditions. Prevalence of comorbidities and associated costs among the CML study population. Comorbidity N % Mean Medical Cost per Patient Heart Disease 297 14.4 $2,590 Arrhythmia 72 3.5 $417 Diabetes 242 11.7 $1,610 Pancreatitis 3 0.2 $12 Lung Disease 157 7.6 $1,933 Pleural Effusion 14 0.7 $298
Abstract 009: Comparative Associations of Peripheral Artery Disease vs. Prevalent Myocardial Infarction or Stroke with Subsequent Mortality in the US Population, NHANES 1999-2004
Authors: Kunihiro Matsushita, Lucia Kwak, Shoshana H Ballew, Maya Salameh, Matthew Allison, Elizabeth Selvin, Josef Coresh
Journal: Circulation (2019)

Background: The FOURIER trial of a PCSK9 inhibitor in patients with prevalent cardiovascular disease reported that patients with peripheral artery disease (PAD) without myocardial infarction (MI) or stroke (MI/stroke) had worse prognosis than those with MI/stroke without PAD. However, whether this observation holds in the general population is unknown. Methods: We conducted a prospective analysis of 5,858 participants aged 40 years or older from the 1999-2004 National Health and Nutrition Examination Survey and compared overall mortality among four categories by PAD (ankle-brachial index ≤0.9) and MI/stroke (self-report) status at baseline using Kaplan-Meier curves and multivariable Cox models adjusted for potential confounders such as age, sex, race, diabetes, smoking, blood pressure, and lipids. Results: There were 125 participants (2.1%) with both PAD and MI/stroke, 323 (5.5%) with PAD without MI/stroke, and 571 (9.7%) with MI/stroke without PAD (4,785 participants without MI/stroke or PAD). During a median follow-up of 9.5 years, 1,133 participants died. Compared to those without PAD or MI/stroke, participants with both MI/stroke and PAD had the worst survival (36.8% at 10 years), followed by those with PAD without MI/stroke (56.4%) and then those with MI/stroke without PAD (71.0%) (Figure). Multivariable Cox models showed similar patterns: adjusted hazard ratios of 2.81 [95% CI 2.16-3.66] in MI/stroke with PAD, 1.85 (1.41-2.43) in PAD without MI/stroke, and 1.59 [1.30-1.95] in MI/stroke without PAD. Conclusions: In the general population, the presence of PAD contributed to significantly higher mortality in those with and without MI/stroke. PAD without MI/stroke showed similar or even worse prognosis than MI/stroke without PAD. These results suggest the importance of recognizing the presence of PAD in the community.
Challenges in Research on Suicide Prevention
Authors: C. Edward Coffey, Brian K. Ahmedani, M. Justin Coffey
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Are oncologists using genome sequencing results to inform patient care?
Authors: Natalie Joanna Bartnik, J. Scott Roberts, Michele Caroline Gornick, Lan Q. Le, Arul M. Chinnaiyan
Journal: Journal of Clinical Oncology (2015)

e12525 Background: Precision oncology relies on genomic sequencing to inform diagnostic and treatment strategies customized to an individual patient. Yet, as genome sequencing becomes more integrated into clinical care, little is known about if and how oncologists are communicating results to patients and using sequence information to alter cancer treatment plans. Methods: Oncologists referring patients with advanced or refractory cancer to the Michigan Oncology Sequencing (MI-ONCOSEQ) study were asked to complete a survey assessing the implications of their patients' genomic sequencing results. After a discussion of the patient’s sequencing results at a multidisciplinary precision medicine tumor board (PMTB), an electronic copy of the research findings and link to an online survey were sent to the referring oncologist. Results: Forty-three oncologists (65% hematology/oncology; 37% female; 12% MD and PhD) who referred 111 adult patients completed the survey (response rate 94%). Most (65%) attended the PMTB meeting when their patient was presented. Upon receiving the MI-ONCOSEQ report, 78% of oncologists indicated that they will not make changes or they are unsure about making changes to their patient’s treatment based on the results (No 51%; Unsure 27%; Yes 22%). The most common reason for not making a change to treatment was a reported lack of locally available trials offering therapies that targeted the relevant genomic finding (41%). Other reasons include the results not presenting clinically significant information (33%) or the patient was responding well to the current treatment regimen (16%). The vast majority of physicians (89%) indicated that they plan to share the sequencing results with their patients. The most frequently reported reason was to better inform the patient about his/her cancer (64%). Conclusions: Most oncologists who refer patients for next generation sequencing plan to communicate results to patients and a subset intend to alter treatment plans based on sequencing results. However, notable barriers to the actionability of results exist (e.g., lack of locally available trials), and more research is needed to understand the process and impact of patient-provider communication about sequencing results.
Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma
Authors: Mohammed Alnaggar, Yan Xu, Jingxia Li, Junyi He, Jibing Chen, Man Li, Qingling Wu, Li Lin, Yingqing Liang, Xiaohua Wang, Jiawei Li, Yi Hu, Yan Chen, Kecheng Xu, Yangzhe Wu, Zhinan Yin
Journal: Journal for ImmunoTherapy of Cancer (2019)

<h3>Background</h3> Cholangiocarcinoma (CCA) is a highly aggressive and fatal tumor. CCA occurs in the epithelial cells of bile ducts. Due to increasing incidences, CCA accounts for 3% of all gastrointestinal malignancies. In addition to comprehensive treatments for cancer, such as surgery, chemotherapy, and radiotherapy, during the past few years, cellular immunotherapy has played an increasingly important role. As a result of our research, we have discovered the γδ T cell-based immunotherapy for CCA. <h3>Case presentation</h3> A 30-year-old male (https://www.clinicaltrials.gov/ ID: NCT02425735) was diagnosed with recurrent mediastinal lymph node metastasis after liver transplantation because of Cholangiocarcinoma (stage IV). In the course of his therapy sessions, he only received allogenic γδ T cell immunotherapy from August, 2017 through February, 2018 (8 infusions in total). γδ T cells were expanded from peripheral blood mononuclear cells (PBMCs) of healthy donor, and ~ 4 × 10<sup>8</sup> cells were adoptive transferred to the patient. <h3>Conclusion</h3> In the above case report of the Cholangiocarcinoma (stage IV) patient who had received liver transplantation and afterward was diagnosed with recurrent mediastinal lymph node metastasis, we clinically proved that allogenic γδ T cell treatment had no adverse effects. We observed that allogenic γδ T cell treatments positively regulated peripheral immune functions of the patient, depleted tumor activity, improved quality of life, and prolonged his life span. After 8 γδ T cell treatments, the size of lymph nodes was remarkably reduced with activity depletion. This clinical work suggested that allogenic γδ T cell immunotherapy could be developed into a promising therapy drug for CCA.
High Post-Transplant Ferritin Level Associates with Adverse Survival and Higher Mortality Rate following Allogeneic Hematopoietic Stem Cell Transplant, whereas Pre-Transplant Ferritin Level Does Not
Authors: Warren Fingrut, Arjun Law, Wilson Lam, Fotios V. Michelis, Santhosh Thyagu, Auro Viswabandya, Rajat Kumar, Jeffrey H. Lipton, Hans A. Messner, Dennis Dong Hwan Kim
Journal: Blood (2018)